KOSPIBiotech & Pharma005500

Samjin Pharmaceutical

₩20,550▲ 21.31%2026-11-18 close
Market Cap
₩273.7B
Turnover
₩16B
Volume
850K
Shares out.
13.3M
PER
8.7×
PBR
0.7×
EPS
₩1,956
Dividend Yield
4.72%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩800 per share · Prices as of the 2026-11-18 close

01

Report overview

Samjin: profit recovery ahead of drug pricing reform

Samjin Pharmaceutical's operating profit rose year on year in the third quarter of 2026, but its domestic, generic-heavy sales base faces a drug pricing reform scheduled for the second half of 2026.

  1. 1

    Full-year 2025 revenue reached KRW 309.1 billion and has risen for three straight years since 2023, while operating profit fell 15.3% to KRW 26.8 billion.

  2. 2

    Third-quarter 2026 revenue was KRW 84.1 billion and operating profit was KRW 11.9 billion, up 22.0% year on year, with operating profit rising for two consecutive quarters since the second quarter.

  3. 3

    The first quarter of 2026 marked the low point, with revenue of KRW 68.1 billion and operating profit of KRW 3.59 billion as demand for respiratory treatments fell.

  4. 4

    The drug pricing reform is the largest variable, as press reports said the industry proposed a 10% cap on cuts while the Ministry of Health and Welfare was reported to hold to its original plan.

  5. 5

    Launches of anticancer and CNS-area new products, along with pending injectable approvals, are the key tasks the company has put forward as the basis for recovery.

02

Business structure

Samjin Pharmaceutical was founded in 1968 for drug manufacturing and trading and listed on the KOSPI in 1988, holding general, prescription and bulk pharmaceutical products.

Based on 2025 results, tablets accounted for 54.3% of revenue, injectables for 15.1% and capsules for 12.4%, so prescription drugs (ETC), including injectables and capsules, exceeded 80% of sales. Health functional foods and other merchandise sales made up 11.8%, and bulk drug sales only 5%.

Its flagship tablets are the antithrombotic Flaris and the analgesic Gebolin, followed by the cerebral function improver Newtirin and the appetite stimulant Trestan. Domestic sales were about 98% of 2024 revenue, and wholesalers and hospitals are the main distribution channels.

Third-quarter 2026 tablet sales were KRW 46.4 billion, up 7.1% from KRW 43.3 billion a year earlier, while injectable sales fell 17.1% to KRW 10.6 billion in the same period. Merchandise sales rose 11.3% to KRW 13.1 billion.

In 2025 the company set up an anticancer and pulmonary arterial hypertension business unit to expand into higher-complexity treatment areas. Among mid-sized domestic pharma companies, it is often described as sensitive to drug pricing policy because its generic and improved-new-drug share is high.

Industry estimates of the generic share of sales differ, with some placing it in the 60% range and others at 70% to 80%.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩83.1B₩9.8B11.8%
2025Q4₩80.5B₩4.2B5.2%
2026Q1₩68.1B₩3.6B5.3%
2026Q2₩79.6B₩7.2B9.0%
2026Q3₩84.1B₩11.9B14.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩274B₩23.2B₩21.9B8.5%8.0%47.4%
2023₩292.1B₩20.5B₩18.9B7.0%7.1%58.2%
2024₩308.3B₩31.6B₩39.2B10.3%15.0%62.5%
2025₩309.1B₩26.8B₩24.2B8.7%8.3%62.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a DART annual-report basis, revenue rose from KRW 274 billion in 2022 to KRW 292.1 billion in 2023 (up 6.6% year on year), KRW 308.3 billion in 2024 (up 5.6%) and KRW 309.1 billion in 2025 (up 0.3%).

Revenue has increased for three consecutive years from 2023 through 2025, and 2025 is the largest year in the 2022 to 2025 span. Operating profit was KRW 23.2 billion in 2022, KRW 20.5 billion in 2023 (down 11.6%), KRW 31.6 billion in 2024 (up 54.4%) and KRW 26.8 billion in 2025 (down 15.3%).

Operating margin was 8.5%, 7.0%, 10.3% and 8.7% in the same years. The company attributed the 2024 operating profit increase to steady growth across all business divisions.

Profit attributable to controlling shareholders reached KRW 39.2 billion in 2024 (up 107.5%), a figure that included a KRW 24.3 billion corporate tax refund and therefore a base effect. It then fell 38.4% to KRW 24.2 billion in 2025, which the company explained as a base effect.

Cost pressure from a higher share of merchandise sales and rising raw material costs were cited for the 2025 profit decline. Operating cash flow was KRW 17.3 billion in 2022, KRW 8.33 billion in 2023, KRW 38.2 billion in 2024 and KRW 24.1 billion in 2025.

The debt ratio rose from 47.4% in 2022 to 62.0% in 2025, and equity of KRW 290.4 billion at the end of 2025 was entirely attributable to controlling shareholders.

Quarterly operating profit fell from KRW 9.78 billion in the third quarter of 2025 to KRW 4.22 billion in the fourth quarter (down 56.8% from the prior quarter), then to KRW 3.59 billion in the first quarter of 2026, before recovering to KRW 7.15 billion in the second quarter and KRW 11.9 billion in the third quarter.

The first-quarter 2026 profit decline reflected a base effect from one-off tax refund gains in the first quarter of 2025, on top of weaker demand for respiratory treatments. Profit attributable to controlling shareholders over the last four quarters totals KRW 24.6 billion.

05

Industry analysis

The largest variable for the company's market is the drug pricing reform. The Ministry of Health and Welfare announced an improvement plan including price cuts in November 2025, described as the first broad reduction since the 2012 across-the-board cut, to take effect in the second half of 2026.

Under the government plan reported at the time, lowering the generic pricing ratio from 53.55% of the original drug price to the 40% range would cut generic prices by about 25% from current levels.

Press calculations put the resulting annual generic-related revenue loss at around KRW 30 billion, and possibly close to KRW 40 billion. The industry proposed a 10% cap on cuts, but as of a March 2026 report the Ministry was reported to be holding to its original proposal.

Samjin Pharmaceutical is often cited as one of the mid-sized pharma companies most exposed to price cuts. Separately, fewer respiratory infections reduced demand for respiratory treatments in the first quarter of 2026, a seasonal and demand factor rather than a policy one.

On the competitive side, the company is widening its range into anticancer, CNS, higher-value treatment areas and co-promotion products. In a January 2026 report, Heungkuk Securities said this pricing cycle is a time to prove business competitiveness as much as the size of earnings.

06

Outlook

The company has put forward anticancer and CNS-area new product launches as the basis for recovery. A company official said that once supply of the new products is in full swing, they would offset the earlier sales decline and show a recovery in profitability.

Injectables are going through product approvals in turn so that production at the Osong plant can return to normal, and the company said output will gradually increase as approvals are completed.

Its pipeline includes 16 new drug projects, and it has won a national research project worth more than KRW 10 billion, with part of its R&D costs funded by the government. In February 2026 it filed an investigational new drug plan with the Ministry of Food and Drug Safety for SJN 314, an immune-inflammatory candidate.

Since the second half of 2025 it has also run a joint AI-based obesity drug study with Namu ICT. In a January 2026 report, Heungkuk Securities projected 2026 revenue of KRW 325.1 billion (up 5.4%), operating profit of KRW 29.0 billion (up 10.9%) and an operating margin of 8.9%.

That projection came before the first-quarter 2026 results were disclosed on May 15, 2026, when first-quarter revenue fell 3.9% year on year. The company said it will gradually improve the higher selling and administrative expenses that came with its diversification.

As of a 2024 report, it had signed partnerships with overseas drugmakers in Vietnam and Canada to expand its overseas revenue share.

07

Valuation

PER
8.7×
PBR
0.7×
ROE
8.7%
EPS
₩1,956
BPS
₩24,298
Dividend per share
₩800

Valuation is best read through the relationship between the current share price level and the earnings trend. Price-to-book is below 1x, which should be viewed alongside the fact that all KRW 290.4 billion of equity at the end of 2025 belongs to controlling shareholders.

A share price below net asset value shows where the stock sits on an asset basis but does not by itself settle the question of profitability. On an earnings basis, profit attributable to controlling shareholders over the last four quarters totals KRW 24.6 billion and forms the denominator of the multiple.

Because controlling-shareholder profit fell 38.4% in 2025 and the 2024 figures included a tax refund, base effects should be considered when comparing annual earnings. After the first-quarter 2026 low, operating profit rose in the second and third quarters, which can change how earnings-based multiples are read.

On dividends, Heungkuk Securities pointed to a stable dividend yield as a positive factor in a January 2026 report. The company completed a treasury share cancellation in November 2025. How much the pricing reform reduces earnings capacity will determine how the same share price reads on multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

New launches and injectable approvals

Whether the anticancer and CNS-area new product launches translate into a recovery in results is the next point to check. Injectable approvals are advancing in turn at the Osong plant, and output is expected to grow gradually once they are complete.

Sixteen new drug projects and a national research project worth more than KRW 10 billion are cited as easing part of the R&D burden.

Third-quarter 2026 profit recovery

Third-quarter 2026 operating profit was KRW 11.9 billion, up 22.0% year on year, and has risen for two consecutive quarters since the second quarter. Lower selling and administrative expenses and higher financial income from reduced borrowings were cited as drivers of the improvement. Tablet sales rose 7.1% to KRW 46.4 billion and led top-line growth.

Cash flow improvement and shareholder returns

Operating cash flow in the first quarter of 2026 widened to KRW 12.5 billion from KRW 4.9 billion a year earlier. Outflows from investing activities narrowed, and the debt ratio fell from 68.6% to 63%, according to press reports. A treasury share cancellation completed in November 2025 also supported shareholder returns.

09

Bear factors

Revenue directly exposed to pricing policy

Samjin's sales base is weighted to generics and improved new drugs, so it is directly exposed to pricing policy. Press calculations said that under the government plan, generic-related revenue could fall by roughly KRW 30 billion a year and possibly close to KRW 40 billion. Exports at about 2.2% of sales were cited as too small to absorb the cuts.

Flat top line and volatile profit

Operating profit fell 15.3% to KRW 26.8 billion in 2025, and first-quarter 2026 revenue fell 3.9% year on year to KRW 68.1 billion. Operating profit in the same quarter dropped 25.8% to KRW 3.59 billion, and operating margin narrowed to 5.3%.

Whether the respiratory demand drop was temporary, and whether the recovery seen through the third quarter of 2026 continues, remain open questions.

Cost pressure and balance sheet strain

Cost burdens from a higher share of merchandise sales and rising raw material costs persist. The first-quarter 2026 cost ratio rose to 63.2% from 60.7% a year earlier. The debt ratio climbed from 47.4% in 2022 to 62.0% in 2025, and a build-up of inventory and borrowings has been reported as a working-capital burden.

10

Risk factors

Drug pricing risk

Whether the second-half 2026 pricing reform takes effect, and how deep the cuts go, is the largest variable. As of press reports, the industry's 10% compromise line and the Ministry's original plan were at odds. With a high generic share, the impact of cuts would flow directly into revenue and profit.

Seasonality and new-product timing

Respiratory treatments swing sharply from quarter to quarter with the infection cycle, as the first quarter of 2026 showed. If new product supply comes later than planned, the pace at which they offset the decline in existing sales could also slow.

Financial and working-capital strain

The debt ratio was 62.0% in 2025, above 47.4% in 2022. Higher inventory and borrowings have been reported as a working-capital burden. Operating cash flow widening in the first quarter of 2026 partly cushions this strain.

11

What to watch next

  1. Around late December 2026 (timing of the pricing reform)

    This is the point to confirm the final pricing reform, its effective date and the adjustment to the generic pricing ratio. The outcome will change generic revenue and later earnings estimates.

  2. Around late March 2027 (2026 annual report filing deadline)

    The fourth-quarter and full-year 2026 results become confirmed reported figures at this point. The check covers fourth-quarter operating profit after the KRW 11.9 billion of the third quarter and the annual operating margin trend.

  3. Mid-May 2027 (first-quarter 2027 results)

    This is the point to see whether anticancer and CNS new product sales start showing up in results and whether injectable output is expanding. The year-on-year recovery against first-quarter 2026 revenue of KRW 68.1 billion also serves as a benchmark.

12

Overall view

Samjin Pharmaceutical is a domestically focused drugmaker whose sales are built on tablets, injectables and capsules, with merchandise sales and bulk drugs added on top.

Revenue on a DART annual-report basis reached KRW 309.1 billion in 2025 and has risen for three consecutive years, but operating profit fell 15.3% to KRW 26.8 billion, so sales and profitability moved in different directions.

The first quarter of 2026 marked the low point on weaker respiratory treatment demand, and operating profit rose in the second and third quarters. Positive factors include new product launches, progress on injectable approvals, higher financial income from lower borrowings and wider cash flow.

Negative factors include exposure of generic-weighted sales to pricing policy and cost pressure from a larger merchandise share. The second-half 2026 pricing reform is the largest variable that could affect both of these, and the earnings path could differ widely depending on the size and timing of the cuts.

Valuation should be read through earnings-based multiples and the share price relative to net assets, with the base effect from the 2024 tax refund taken into account. The next checkpoints are the annual results to be confirmed in the 2026 annual report and first-quarter 2027 results. This report is provided for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. bloter.net
  2. dealsite.co.kr
  3. bloter.net
  4. v.daum.net
  5. news.nate.com
  6. newstong.co.kr
  7. m.news.nate.com
  8. medipana.com
  9. thebionews.net
  10. dealsite.co.kr
  11. comp.wisereport.co.kr
  12. bloter.net
  13. medicopharma.co.kr
  14. etnews.com
  15. m.thinkpool.com
  16. youthdaily.co.kr
  17. dailyinvest.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis